Product Program year 2024 Source: CMS Open Payments

ProHance

Drug Diagnostic Imaging

NDC 0270-1111-04

Open in the dashboard

General payments

$35,846

19 payments

Research payments

$288,803

8 payments

Through program year 2024, $35,846 in general payments and $288,803 in research payments were reported against ProHance (Diagnostic Imaging).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2024 Research $170,937 1
2022 General $148 4
2022 Research $3,583 2
2021 General $27,509 10
2021 Research $10,045 1
2020 General $8,190 5
2020 Research $104,238 4

Breakdown

Who paid General payments · program years 2020–2022
  1. Bracco Diagnostics Inc. $35,846 19 payments
Top recipients General payments · program year 2022
  1. Kim Eubanks Family Medicine · Decatur, GA $37 25% · 1 payment
  2. Unni Udayasankar Pediatric Radiology · Tucson, AZ $37 25% · 1 payment
  3. David Aria Diagnostic Radiology · Philadelphia, PA $37 25% · 1 payment
  4. Geoffrey Rubin Diagnostic Radiology · Tucson, AZ $37 25% · 1 payment

Each share is of general payments naming this product in 2022.

Specialties paid General payments · program year 2022
  1. Diagnostic Radiology Radiology $74 50% · 2 practitioners
  2. Family Medicine $37 25% · 1 practitioner
  3. Pediatric Radiology Radiology $37 25% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2022
  1. Arizona $74 50% · 2 recipients
  2. Georgia $37 25% · 1 recipient
  3. North Carolina $37 25% · 1 recipient

Each share is of general payments naming this product in 2022 where a state was reported.

Given in the clinic

Part B · billing codes
Medicare Part B billing codes matched to ProHance
Billing code Providers Services Paid by Medicare
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 651 664,794 $766,665
Injection, gadoteridol, (prohance multipack), per ml A9576 329 254,995 $289,666

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

19 general · 8 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record